MarketLens

Forte Biosciences' Vitiligo Triumph: A High-Stakes Bet on Broad Autoimmune Potential

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Blue Origin's $130 Billion Valuation: A High-Stakes Bet on Future Potential, Not Current Performance

1 months ago

Neuronetics: A High-Stakes Turnaround Play with 143% Upside Potential

1 months ago

Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

3 months ago

Unusual Machines: A High-Stakes Bet on the U.S. Drone Boom's Promise

2 months ago

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

Roivant Sciences' $4.7B pro forma liquidity supports its shift to commercial-stage biopharma, eliminating near-term dilution risk. Brepocitinib's FDA Priority Review for dermatomyositis, with potentia...

ROIV

Stock News•1 months ago

Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover

Argenx agreed to buy Forte Biosciences in an all-cash deal, gaining a promising autoimmune drug candidate to bolster its pipeline.

FBRX

Stock News•1 months ago

Q32 Bio: Bempikibart's Progress Keeps Me Bullish

Q32 Bio's bempikibart showed meaningful hair regrowth in severe alopecia areata, including JAK-experienced patients, with durable benefits after treatment cessation. The safety profile could different...

QTTB

Stock News•1 months ago

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

Forte Biosciences' FB102 showed statistically significant improvement in vitiligo at Week 24, after a 12-week treatment period, signaling potential efficacy.

FBRX